Browse studies

Find your next paid study

103 recruiting studies matching your filters

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 …

Non-alcoholic Fatty Liver Disease

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07221188

Observational

Exercise Training Decreases Alcohol Consumption and Tissue Injury by an FGF21-dependent Mechanism

This randomized study will examine whether a 12-week supervised home-based endurance exercise program can reduce alcohol use and alcohol craving in adults with…

Alcohol Use Disorder (AUD)Alcohol Related Liver Disease

Estimated

~$10 – $6,250

The Cleveland ClinicNCT07824089

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO…

Alcoholic HepatitisAlcohol-related Liver Disease

Estimated

~$10 – $1,050

HepQuant, LLCNCT07060547

Observational

Effect of Behavioral Intervention/Therapy to Reduce Diabetes and Liver Disease Risk Through Prescribed Digital Therapeutics Enabled by AI/ML Powered Predictive Analytics

This clinical trial aims to find out if a digital behavioral program, delivered through the SIPPA digital therapeutics app, can help improve blood sugar contro…

Type 2 DiabetesLiver Disease

Estimated

~$10 – $8,750

SIPPA Solutions INCNCT07032311

Phase 1

A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis…

Cholestatic Liver Disease

Estimated

~$10 – $8,750

Zydus Therapeutics Inc.NCT06825559

Phase 1

A Phase 1, Open-Label Extension Groups Study in Subjects Having Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

Hepatic ImpairmentCirrhosisCholestatic Liver Disease

Estimated

~$10 – $8,750

Zydus Therapeutics Inc.NCT05045482

OPERA Longitudinal Observational Database in the Study of Chronic Diseases, Treatments and Outcomes

Greater advances are needed in two separate but related areas in healthcare: 1) the Clinical Decision Support Systems that complement the EHR use in support of…

Chronic DiseaseHIV/AIDSLiver Diseases+4 more

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adul…

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Estimated

~$10 – $8,750

89bio, Inc.NCT06318169

Observational

Peer Support to Enhance Care for Liver Transplant Recipients Who Had Alcohol-Associated Liver Disease

Liver transplant (LT) recipients with a history of alcohol-related liver disease (ALD) may encounter various psychosocial and medical challenges during post-LT…

Alcohol Use DisorderAlcohol Related Liver DiseaseLiver Transplant Recipient

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07397598

Phase 1

Human Models of Selective Insulin Resistance: Alpelisib, Part I

The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 d…

Insulin ResistancePrediabetic StateOverweight and Obesity+1 more

Estimated

~$10 – $6,250

Columbia UniversityNCT06354088

Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chroni…

Autoimmune Liver DiseasePrimary Sclerosing CholangitisAutoimmune Hepatitis

Estimated

~$10 – $675

Children's Hospital Medical Center, CincinnatiNCT03175471

Longitudinal Study for the Assessment of MRI Based Biomarkers as a Predictors of Clinical Endpoints in Pediatric Onset Autoimmune Liver Disease

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic…

Autoimmune Liver DiseaseAutoimmune HepatitisPrimary Sclerosing Cholangitis

Estimated

~$10 – $675

Children's Hospital Medical Center, CincinnatiNCT03178630